PD-L1Pep-2
£85.00 1mg
Binds to PD-L1.
PD-L1Pep-2 was identified from a phage-displayed library for peptides that selectively bind to PD-L1-overexpressing cells. PD-L1Pep-2 has a binding affinity of 281 nM, and preferentially binds to high PD-L1-expressing cells over low PD-L1-expressing cells, binding further enhanced by interferon-?, an inducer of PD-L1 expression. In animal models, intravenously injected PD-L1Pep-2 efficiently targets tumour tissues, inhibits tumour growth, and increases the CD8+/FoxP3+ ratio in mice. PD-L1Pep-2 in combination with doxorubicin inhibits tumour growth more efficiently than doxorubicin alone. PD-L1Pep-2 blockade of PD-L1 reinvigorates T-cell activity and inhibits tumour growth by enhancing anti-tumour immunity.
Please contact us for availability.
Additional information
Other Names | PD-L1-blocking peptide |
---|---|
Three Letter Sequence | H-Cys-Val-Arg-Ala-Arg-Thr-Arg-OH |
Molecular Weight | 860.48 |
Molecular Formula | C33H64N16O9S |
Sequence | CVRARTR |
Solubility | Soluble in water |
Appearance | Freeze dried solid |
Storage | Store dry, frozen and in the dark |
Purity | >95% by HPLC |
Searchable Words | PD-L1Pep-2, PP-380, PP380, CVRARTR, PD-L1-blocking peptide |